Processa Pharmaceuticals (PCSA) Stock Price
Processa Pharmaceuticals Price
Revenue at Processa Pharmaceuticals has contracted by 42.3% per year over the past 6 years to 5,000.00 USD. Processa Pharmaceuticals's net margin stands at -7,580.0%, down from -1,441.1% several years earlier. Analysts set a median price target of 1.02 USD, implying 44.6% below the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 25% above its 52-week low.
Processa Pharmaceuticals stock price
Processa Pharmaceuticals business model & stock analysis
Frequently asked questions about Processa Pharmaceuticals
Analysts currently set an average price target of 1.02 USD for the Processa Pharmaceuticals stock (median: 1.02 USD), implying -44.6 % versus the latest price. The consensus is based on 8 analyst ratings.
7 analysts currently rate the Processa Pharmaceuticals stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Processa Pharmaceuticals to generate revenue of 10.01 M USD and earnings per share of -6.00 USD.
Converted at the current exchange rate, the Processa Pharmaceuticals share trades at 1.61 EUR (1.84 USD).
The Processa Pharmaceuticals share (PCSA) is listed on 1 stock exchanges, including: NASDAQ (PCSA).
No history available for Processa Pharmaceuticals.
The expected revenue of Processa Pharmaceuticals is 10.01 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Processa Pharmaceuticals is -734,400.03 USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Processa Pharmaceuticals is currently -0.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Processa Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Processa Pharmaceuticals is currently 0.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Processa Pharmaceuticals stock.
The Eulerpool Quality Score for Processa Pharmaceuticals is 2/10.
The ISIN of Processa Pharmaceuticals is US74275C4033. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Processa Pharmaceuticals is PCSA. The ticker symbol is used to trade Processa Pharmaceuticals shares on the stock exchange.
Processa Pharmaceuticals paid dividends every year for the past 0 years.
Processa Pharmaceuticals is assigned to the 'Health' sector.
The dividends of Processa Pharmaceuticals are distributed in USD.
Processa Pharmaceuticals stock
Processa Pharmaceuticals Peer Group
Processa Pharmaceuticals Ticker
All fundamentals and in-depth analysis of Processa Pharmaceuticals
Our stock analysis for Processa Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Processa Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.